Laboratory Monitoring for Rheumatoid Arthritis Patients

Medication Monitoring Labs

The American College of Rheumatology recommends monitoring labs for patients on Methotrexate, Leflunomide, or Sulfasalazine, including CBC, liver transaminases, and serum creatinine, every 2-4 weeks during the first 3 months of therapy or after dose increases 1
For patients on Methotrexate, Leflunomide, or Sulfasalazine, monitoring labs should be done every 8-12 weeks between 3-6 months of stable therapy, and every 12 weeks after 6 months of stable therapy 1
Patients with comorbidities, abnormal lab results, or multiple therapies may require more frequent testing than these general intervals 1
For patients on Hydroxychloroquine, no routine laboratory monitoring is required after baseline labs 1
For patients on NSAIDs, CBC, liver function tests, and renal function tests should be done every 6-12 months 2, 3
For patients on Tocilizumab or Tofacitinib, lipid profiles should be obtained at baseline and monitored periodically 2, 3

The American College of Rheumatology recommends screening for latent infections, including tuberculosis, before starting biologic therapy 4
Tuberculin skin test or interferon-gamma release assay should be done regardless of risk factors, with IGRA preferred over TST in patients with prior BCG vaccination 4
Annual TB testing is required for patients on biologics who live, travel, or work where TB exposure is likely 4
Hepatitis B surface antigen, surface antibody, and core antibody, as well as hepatitis C antibody, should be tested before starting biologic therapy 4, 5

C-reactive protein is preferred over ESR as it is more reliable and not age-dependent, and should be repeated at each visit to monitor disease activity 5
CBC with differential should be repeated periodically to assess for cytopenias and calculate neutrophil-to-lymphocyte ratio 5

A comprehensive metabolic panel, including liver function tests, renal function, glucose, and uric acid levels, should be done for baseline assessment 5
Urinalysis should be part of the initial workup to assess renal involvement 5, 6

Pregnancy testing should be considered before starting therapy with teratogenic medications, such as methotrexate or leflunomide, and counseling on effective contraception is mandatory 2, 3

Acute phase reactants, such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), are incorporated into composite disease activity measures (DAS28-ESR, DAS28-CRP, SDAI) that guide treatment decisions, as recommended by the American College of Rheumatology 7, 8

Laboratory tests complement but do not replace clinical assessment using composite disease activity measures, and the American College of Rheumatology recommends using validated measures (CDAI, DAS28-ESR/CRP, SDAI, RAPID-3, PAS, PAS-II) that incorporate joint counts, patient global assessment, and inflammatory markers to guide treat-to-target strategies 7, 8, 9
Regular follow-up should occur every 1-3 months during active disease with therapeutic adaptation to reach remission or low disease activity within 3-6 months, according to the European League Against Rheumatism 9

For patients with rheumatoid arthritis on tocilizumab, the American College of Rheumatology recommends monitoring CBC and liver function tests within the first 1-2 months of starting therapy, then every 3-4 months thereafter, along with lipid profiles every 6 months, with very low certainty of evidence 10
The American College of Rheumatology conditionally recommends this monitoring schedule, which aligns with FDA package insert recommendations, for patients with rheumatoid arthritis on tocilizumab 10